Meridian Bioscience Provides FY 2013 Guidance | GenomeWeb

NEW YORK (GenomeWeb News) - Meridian Bioscience today provided financial guidance for fiscal-year 2013 and reaffirmed its 2012 guidance given just a month ago.

The Cincinnati-based diagnostics firm said that it expects revenues for its fiscal year ended Sept. 30, 2013, to be in the range of $190 million to $195 million. It also anticipates per-share diluted earnings to be between $.86 and $.91.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: experts say race is not a sufficient proxy for studying human genetic diversity and more.

Technology Review writes that CRISPR/Cas9 gene editing firm Editas' success may hinge on a patent case.

Researchers unearthed a bioinformatics error in the Science paper reporting the first ancient African genome, and the authors are seeking an erratum.

A boy's cystic fibrosis carrier status was revealed by a teacher to the parents of children with CF who then sought the boy's transfer to another school, leading to a lawsuit.